EP3328378A4 - Compositions and methods for treating acne - Google Patents

Compositions and methods for treating acne Download PDF

Info

Publication number
EP3328378A4
EP3328378A4 EP16831433.4A EP16831433A EP3328378A4 EP 3328378 A4 EP3328378 A4 EP 3328378A4 EP 16831433 A EP16831433 A EP 16831433A EP 3328378 A4 EP3328378 A4 EP 3328378A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
treating acne
acne
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16831433.4A
Other languages
German (de)
French (fr)
Other versions
EP3328378A1 (en
Inventor
George Liu
Stacey KOLAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of EP3328378A1 publication Critical patent/EP3328378A1/en
Publication of EP3328378A4 publication Critical patent/EP3328378A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/02Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02001Hyaluronate lyase (4.2.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025Nucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16831433.4A 2015-07-30 2016-07-29 Compositions and methods for treating acne Withdrawn EP3328378A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562198904P 2015-07-30 2015-07-30
PCT/US2016/044793 WO2017019982A1 (en) 2015-07-30 2016-07-29 Compositions and methods for treating acne

Publications (2)

Publication Number Publication Date
EP3328378A1 EP3328378A1 (en) 2018-06-06
EP3328378A4 true EP3328378A4 (en) 2019-06-05

Family

ID=57885058

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16831433.4A Withdrawn EP3328378A4 (en) 2015-07-30 2016-07-29 Compositions and methods for treating acne

Country Status (3)

Country Link
US (1) US20190022207A1 (en)
EP (1) EP3328378A4 (en)
WO (1) WO2017019982A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024145574A2 (en) * 2022-12-30 2024-07-04 Cedars-Sinai Medical Center Vaccines targeting c. acnes hyaluronidase for prophylaxis and treatment of acne vulgaris

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055104A2 (en) * 2000-12-21 2002-07-18 Arkagen, Inc. Acne vaccine
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
WO2014165713A2 (en) * 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055104A2 (en) * 2000-12-21 2002-07-18 Arkagen, Inc. Acne vaccine
WO2009128917A2 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
WO2014165713A2 (en) * 2013-04-03 2014-10-09 Cedars-Sinai Medical Center Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq protein [online] 10 December 2009 (2009-12-10), "Hyaluronan lyase protein sequence SEQ ID NO: 69.", XP002788058, Database accession no. AXR76002 *
DATABASE Geneseq proteins [online] 21 January 2010 (2010-01-21), "Propionibacterium acnes hyaluronidase protein sequence, SEQ ID 69.", XP002788057, Database accession no. AXS99547 *
GATHINGS ET AL: "The treatment of keloids with a combination of hyaluronidase and kutapressin", AMERICAN JOURNAL OF SURGERY, PAUL HOEBER, NEW YORK, NY, US, vol. 88, no. 3, 1 September 1954 (1954-09-01), pages 429 - 430, XP026363685, ISSN: 0002-9610, [retrieved on 19540901] *
HARMONY TYNER ET AL: "Hyaluronidase in Clinical Isolates of Propionibacterium acnes", INTERNATIONAL JOURNAL OF BACTERIOLOGY, vol. 2015, 1 January 2015 (2015-01-01), pages 1 - 6, XP055542837, ISSN: 2356-6957, DOI: 10.1155/2015/218918 *
See also references of WO2017019982A1 *

Also Published As

Publication number Publication date
US20190022207A1 (en) 2019-01-24
EP3328378A1 (en) 2018-06-06
WO2017019982A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
EP3555077A4 (en) Compositions and methods for treating cancer
EP3377516A4 (en) Methods and compositions for treating cancer
EP3532464A4 (en) Compositions and methods for treating ezh2-mediated cancer
EP3302379A4 (en) Compositions and methods for treating pterygium
EP3154566A4 (en) Methods and compositions for treating ulcers
EP3490582A4 (en) Methods and compositions for treating myelofibrosis
EP3277270A4 (en) Compositions and methods for treating anemia
EP3200815A4 (en) Methods and compositions for treating cancer
EP3307296A4 (en) Methods and compositions for treating aging-associated conditions
EP3458079A4 (en) Compositions and methods for treating acne
EP3189074A4 (en) Compositions and methods for treating and preventing inflammation
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3462883A4 (en) Compositions and methods for treating cancer
EP3458099A4 (en) Compositions and methods for treating acne vulgaris
EP3405191A4 (en) Methods and compositions for treating hyperhidrosis
EP3528798A4 (en) Compositions and methods for treating cancer
EP3347025A4 (en) Methods and compositions for cancer treatment
EP3541421A4 (en) Compositions and methods for treating cancer
EP3386594A4 (en) Compositions and methods for treating drug-tolerant glioblastoma
EP3164139A4 (en) Topical compositions and methods for treating wounds
EP3142699A4 (en) Compositions and methods for treating metabolic disorders
EP3468546A4 (en) Compositions and methods for treating cancer
EP3154544A4 (en) Compositions and methods for treating cancers
EP3352729A4 (en) Method and compositions for treating skin
EP3273951A4 (en) Compositions and methods for treating psoriasis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/88 20060101ALI20190124BHEP

Ipc: A61K 38/51 20060101AFI20190124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190506

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/88 20060101ALI20190429BHEP

Ipc: A61K 38/51 20060101AFI20190429BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191203